ArticleCureus2025
Chemotherapy Response as a Predictor of Survival in Post-neoadjuvant Esophagectomy Specimens.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Esophageal carcinoma is one of the most common cancers worldwide, which is conventionally treated with neoadjuvant chemoradiation and surgery. Presurgical treatment impacts outcomes by various factors. Objective This study aims to evaluate the prognostic significance of chemotherapy response in esophagectomy specimens and its association with survival outcomes in a post-neoadjuvant setting. Methods One hundred eighteen in-house post-neoadjuvant chemoradiation resection cases for esophageal carcinoma at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, with a follow-up period of at least six years were included in the study. Clinical T and N stage, current status and sites, and time of disease progression were retrieved from hospital archives. Pathological T and N stage and chemotherapy response scores (CRSs), along with various other factors, were assessed during the histopathological review. Overall survival (OS) and progression-free survival (PFS) were calculated and statistically analyzed by IBM SPSS Statistics for Windows, Version 29 (Released 2021; IBM Corp., Armonk, New York, United States). Results In a study of 118 patients, 68 (57.6%) died. The median OS was 65 months, and the five-year survival rate was 59.6%. Prognostic factors identified in the univariate analysis included age, clinical T stage, pathological T stage, pathological N stage, and CRS. ypT0 had a median survival of 72 months, significantly longer than ypT1 (65 months), ypT2 (36 months), and ypT3 (24 months). Similar trends were observed for improving CRSs. Disease progression occurred in 37 patients (31.35%), with a median PFS of 82.93 months. Multivariate analysis revealed that only CRS score 2 was statistically significant in predicting OS outcomes. Conclusion The study found a positive correlation between improved CRSs and OS/PFS, as well as between decreased pathological T stage and survival. It highlights the need for grading systems to include downstaged lymph nodes in therapy response assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.